Literature DB >> 30591307

Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma.

Jay J Idrees1, Katiuscha Merath1, Faiz Gani2, Fabio Bagante1, Rittal Mehta1, Eliza Beal1, Jordan M Cloyd1, Timothy M Pawlik3.   

Abstract

BACKGROUND: A retrospective study was performed to characterize trends in centralization of care and compliance with National Comprehensive Cancer Network (NCCN) guidelines for resected cholangiocarcinoma (CCA), and their impact on overall survival (OS).
METHODS: Using the National Cancer Database (NCDB) 2004-2015 we identified patients undergoing resection for CCA. Receiver Operating Characteristic (ROC) analyses identified time periods and hospital volume groups for comparison. Propensity score matching provided case-mix adjusted patient cohorts. Cox hazard analysis identified risk factors for OS.
RESULTS: Among the 40,338 patients undergoing resection for CCA, the proportion of patients undergoing surgery at high volume hospitals increased over time (25%-44%, p < 0.001), while the proportion of patients undergoing surgery at low volume hospitals decreased (30%-15%, p < 0.001). Using ROC analyses, a hospital volume of 14 operations/year was the most sensitive and specific value associated with mortality. Surgery at high volume hospitals [HR] = 0.92, 95% CI: 0.88-0.97, p < 0.001) and receipt of care compliant with NCCN guidelines (HR = 0.87, 95% CI: 0.83-0.91, p < 0.001) were independently associated with improved OS.
CONCLUSIONS: Both centralization of surgery for CCA to high volume hospitals and increased compliance with NCCN guidelines were associated with significant improvements in overall survival.
Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30591307     DOI: 10.1016/j.hpb.2018.11.013

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  9 in total

1.  Outcomes After Resection of Hepatocellular Carcinoma: Intersection of Travel Distance and Hospital Volume.

Authors:  Eliza W Beal; Rittal Mehta; Katiuscha Merath; Diamantis I Tsilimigras; J Madison Hyer; Anghela Paredes; Mary E Dillhoff; Jordan Cloyd; Aslam Ejaz; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-05-08       Impact factor: 3.452

2.  Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma.

Authors:  Grace C Lee; T Clark Gamblin; Zhi Ven Fong; Cristina R Ferrone; Lipika Goyal; Keith D Lillemoe; Lawrence S Blaszkowsky; Kenneth K Tanabe; Motaz Qadan
Journal:  Ann Surg Oncol       Date:  2019-07-31       Impact factor: 5.344

3.  Insurance Coverage Type Impacts Hospitalization Patterns Among Patients with Hepatopancreatic Malignancies.

Authors:  Rittal Mehta; Kota Sahara; Katiuscha Merath; J Madison Hyer; Diamantis I Tsilimigras; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Mary Dillhoff; Allan Tsung; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-06-13       Impact factor: 3.452

4.  Defining Facility Volume Threshold for Optimization of Short- and Long-Term Outcomes in Patients Undergoing Resection of Perihilar Cholangiocarcinoma.

Authors:  Mohamedraed Elshami; Jonathan J Hue; Fasih Ali Ahmed; Hanna Kakish; Richard S Hoehn; Luke D Rothermel; Jeffrey M Hardacre; John B Ammori; Jordan M Winter; Lee M Ocuin
Journal:  J Gastrointest Surg       Date:  2022-09-22       Impact factor: 3.267

5.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

6.  Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.

Authors:  Peng Liao; Li Cao; Hang Chen; Shui-Zi Pang
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

Review 7.  Moving forward in the treatment of cholangiocarcinoma.

Authors:  Tommaso M Manzia; Alessandro Parente; Ilaria Lenci; Bruno Sensi; Martina Milana; Carlo Gazia; Alessandro Signorello; Roberta Angelico; Giuseppe Grassi; Giuseppe Tisone; Leonardo Baiocchi
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

8.  Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report.

Authors:  Shu-Guang Zhu; Hai-Bo Li; Tian-Xing Dai; Hua Li; Guo-Ying Wang
Journal:  World J Clin Cases       Date:  2022-09-26       Impact factor: 1.534

Review 9.  Appraisal of the current guidelines for management of cholangiocarcinoma-using the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument.

Authors:  Paschalis Gavriilidis; Alan Askari; Keith J Roberts; Robert P Sutcliffe
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.